from web site
The pharmaceutical landscape in Germany has actually seen a significant shift recently with the introduction and rising appeal of GLP-1 (Glucagon-like peptide-1) receptor agonists. Initially developed to deal with Type 2 diabetes, medications like Ozempic and Wegovy have acquired worldwide fame for their weight loss efficacy. For locals and migrants in Germany, comprehending the expense, repayment structure, and availability of these drugs is necessary.
Germany runs under a distinct two-tier healthcare system including statutory health insurance (Gesetzliche Krankenversicherung or GKV) and personal health insurance coverage (Private Krankenversicherung or PKV). This structure, integrated with rigorous federal guidelines on pharmaceutical rates, makes the expense of GLP-1 medications in Germany rather various from that in the United States or other European countries.
GLP-1 receptor agonists are a class of medications that imitate a natural hormonal agent in the body. They operate by:
Typical GLP-1 medications readily available in Germany consist of:
In Germany, the rate of a medication is highly reliant on whether it is being utilized for its main medical sign (like Type 2 diabetes) or as a "lifestyle" treatment (like weight-loss).
If a patient has Type 2 diabetes, the GKV normally covers the cost of medications like Ozempic or Rybelsus. In this case, the patient pays only a little co-payment (Zuzahlung), generally ranging from EUR5 to EUR10 per prescription.
However, for weight management, the circumstance changes. Under Section 20 of the Social Code Book V (SGB V), medications mainly meant for "enhancing the quality of life" or weight reduction are presently excluded from GKV protection. This means patients utilizing Wegovy or Saxenda for weight reduction must normally pay the full retail cost out-of-pocket.
Private insurance providers have more flexibility. Depending on the specific tariff and medical need, some private insurers might compensate the cost of weight-loss medications if the patient meets particular criteria, such as a high BMI (normally >> 30 )and accompanying comorbidities (high blood pressure, sleep apnea).
The following table provides a price quote of out-of-pocket costs for the most popular GLP-1 medications in Germany as of late 2023/early 2024. Costs might differ a little in between drug stores but are controlled by the Arzneimittelpreisverordnung (Medicines Price Ordinance).
| Medication | Main Usage | Form | Approx. Month-to-month Cost (Self-Pay) |
|---|---|---|---|
| Ozempic | Type 2 Diabetes | Weekly Injection | EUR80 - EUR90 |
| Wegovy (Low Dose) | Weight Loss | Weekly Injection | EUR170 - EUR190 |
| Wegovy (High Dose) | Weight Loss | Weekly Injection | EUR300 - EUR320 |
| Mounjaro | Diabetes/ Obesity | Weekly Injection | EUR260 - EUR330 |
| Saxenda | Weight Loss | Daily Injection | EUR250 - EUR300 |
| Rybelsus | Type 2 Diabetes | Daily Tablet | EUR100 - EUR140 |
Note: Costs represent the "Apothekenverkaufspreis" (Pharmacy Retail Price) for clients with a personal prescription.
Wegovy was introduced in Germany in July 2023. Unlike the United States, where costs can surpass ₤ 1,000 each month, the German market take advantage of government-negotiated prices, though it remains costly for the typical customer.
The expense of Wegovy in Germany scales slightly with the dosage. A basic 4-week supply includes one pen that enables 4 dosages.
Typical Wegovy Price Tiers:
The variation between German and American drug costs is a regular topic of debate. The lower expenses in Germany are attributed to:
Despite whether a patient is paying out-of-pocket or through insurance, GLP-1 medications are prescription-only (verschreibungspflichtig).
Germany, like the remainder of the world, has actually dealt with significant shortages of Ozempic. Because Ozempic is much cheaper than Wegovy (approx. EUR80 vs EUR170+), numerous clients looked for "off-label" prescriptions for weight reduction.
To combat this, the German Federal Institute for Drugs and Medical Devices (BfArM) has actually provided guidelines urging physicians to only recommend Ozempic for its approved indicator: Type 2 Diabetes. This is to guarantee that diabetic patients do not lose access to their life-saving medication.
Presently, no. Wegovy is categorized as a "way of life drug" in Germany. Regardless of recent conversations in the Bundestag regarding the rising expenses of obesity, the statutory medical insurance funds are lawfully barred from covering obesity-only medications.
Yes. Any licensed pharmacy in Germany (consisting of online pharmacies like DocMorris or Shop Apotheke) can meet a private prescription for GLP-1 medications, offered they have the stock.
Yes, Mounjaro was just recently introduced in the German market. Website is available in the "KwikPen" format. Costs are presently higher than Ozempic however competitive with Wegovy's upkeep doses.
Beyond the medication, patients need to represent the cost of the medical professional's assessment. For GKV clients, this is covered. For private/self-pay patients, an assessment can cost in between EUR30 and EUR100 depending on the intricacy of the examination.
No. It is prohibited and highly unsafe to acquire these medications without a prescription. Germany has rigorous laws against "Fernabsatz" (mail order) of prescription drugs from non-certified sources. Fake Ozempic pens have been discovered in the European supply chain.
If you are considering GLP-1 treatment in Germany, keep the following points in mind:
The cost of GLP-1 medications in Germany reflects the country's wider technique to healthcare: managed, reasonably economical compared to the worldwide market, but strictly segmented between medical necessity and elective treatment. While diabetic clients take advantage of really low co-payments, those looking for these drugs for weight reduction must be gotten ready for a substantial month-to-month investment. As clinical evidence continues to reveal the long-lasting health benefits of weight reduction, numerous in the German medical neighborhood hope for a shift in insurance legislation that might one day make these treatments more available to all.
